HDAC9 and benign prostatic hyperplasia: Due to the significant role of epigenetic mechanisms in BPH pathophysiology, emerging therapeutic approaches are targeting these alterations, including DNA methylation inhibitors (37), histone deacetylase (HDAC) inhibitors (38), and micRNA-based (39) therapies to reduce fibrosis and slow BPH progression.